Prdx2 suppresses the erythroid differentiation by modulating the ROS-JNK1 signaling axis.
These findings establish PRDX2 as a critical regulator of erythroid differentiation blockade and identify PRDX2 as a promising pharmacologically actionable target for differentiation-based therapy in erythroleukemia.